Led · Equity · Jul 2024

Montage Gold is a precious-metals explorer and developer. On July 18, 2024 the company announced that Zijin Mining will acquire a 9.9% equity stake. The purchase price is reported as nearly CA$57.3 million (approximately RMB 305 million). The transaction is described in the report as a strategic investment. The article cites IT桔子 (IT Juzi) as the source of the information. No operating metrics, use of proceeds, prior financings, founding year, or location details are provided in the article.

Led · Series C · Mar 2024

Yikong Zhijia specializes in unmanned driving technology for mining vehicles and offers full‑stack autonomous solutions and transport operation services for open‑pit mines. The company has developed a “4+2” solution: four core products (line‑control mining trucks, an intelligent cloud‑control platform, vehicle‑side autonomous driving systems, and a collaborative operation system) and two service modes (engineering operation and technology operation). It has deployed multi‑train, 24‑hour unmanned driving operations at large open‑pit coal mines under National Energy Group and Tebian Electric. Yikong Zhijia emphasizes real‑world operations to create a data loop and refine its technology. The company plans to use new funding to advance technical product development and improve unmanned driving operation management. Eacon Mining Technology provides full-stack autonomous driving technology and haulage services to mining operations. Founded in May 2018 by Lei Zhang and based in Beijing, the company combines autonomous driving technology with on-site operational capabilities to modernize traditional mining. Eacon currently operates 304 autonomous trucks that have driven a total of 4.2 million kilometers autonomously and has maintained an impeccable safety record for over five years. The company has established an office in Perth, Australia and plans to broaden its presence in additional overseas markets. It raised $55.22M in a financing round and intends to use the proceeds to expand operations and its business reach, bringing total funding to $62.13M.

Led · Series A · Feb 2024

Depu CNC (德普数控) develops, manufactures and sells high-end five-axis CNC machine tools and their key components. The company’s core R&D team comes from well-known domestic and international machine-tool firms with extensive product-development experience. It has in-house capabilities for core five-axis components including rotary tables, tilting heads, position-detection modules, tool magazines and optical probes, and has developed G, V and U series machines. Depu has exported products to Europe, is delivering orders to a Fortune Global 500 customer, and reports that its high-end five-axis linked machines are in mass production. The company’s sales network covers the Yangtze River Delta, the Pearl River Delta and overseas markets, and it has a cooperative development arrangement with Bosch Rexroth. New funding will be used to support R&D, operations management and team building.

Participated · Series C · Jan 2024

Hengrui Yuanzheng focuses on developing immunocellular therapies for solid tumors, with multiple product pipelines including MASCT, TCR-T, and TCR bispecific candidates. Its MASCT program is described as the world’s first clinically approved multi‑target cell therapy for solid tumors and has entered Phase II clinical trials. The company is actively advancing those clinical programs while maintaining a pipeline of next‑generation TCR‑based approaches. Recent financing activity shows continuing investor support. Hengrui Yuanzheng completed a C+ round of financing totaling nearly ¥100 million. The reported investors include Zijin Port Capital, which continued to follow on, alongside Zhongke Kechuang and other institutional backers. Hengrui Yuanzheng focuses on immunocyte therapies for solid tumors, developing multiple product lines including MASCT, TCR-T and TCR bispecifics. Its MASCT program is the world’s first clinically approved multi-target cell therapy for solid tumors and has entered Phase II. The company’s ReGET platform (Reverse Genetic Engineering of TCR-T) enables rapid isolation of high-affinity TCRs from patients and has generated extensive TCR data based on Asian HLA types. Hengrui Yuanzheng’s lead TCR-T candidate, HRYZ-T101, received an IND from the CDE and has China and US patents plus broad PCT coverage. The firm built a Shanghai Songjiang headquarters and a Yangtze River Delta regional cell preparation center in 2021. Financially, it has completed multiple financings and recently closed a C round of over RMB 200 million.